Evidence map›Paper›PMID 35562783›Full record

ArticleImplementation science communications2022

A type III effectiveness-implementation hybrid evaluation of a multicomponent patient navigation strategy for advanced-stage Kaposi's sarcoma: protocol.

Sigrid Collier, Aggrey Semeere, Helen Byakwaga, Miriam Laker-Oketta, Linda Chemtai, Anjuli D Wagner, Ingrid V Bassett, Kara Wools-Kaloustian, Toby Maurer, Jeffrey Martin and 2 more

Open access · goldAbstract read
In one paragraph

Article in Implementation science communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Sigrid CollierUniversity of Washington, Seattle, WA, USA. coll0640@uw.edu.ORCID http://orcid.org/0000-0002-4143-0408
Aggrey SemeereInfectious Disease Institute, Kampala, Uganda.
Helen ByakwagaInfectious Disease Institute, Kampala, Uganda.
Miriam Laker-OkettaInfectious Disease Institute, Kampala, Uganda.
Linda ChemtaiAcademic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya.
Anjuli D WagnerUniversity of Washington, Seattle, WA, USA.
Ingrid V BassettMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Kara Wools-KaloustianIndiana University, Indianapolis, IN, USA.
Toby MaurerIndiana University, Indianapolis, IN, USA.
Jeffrey MartinUniversity of California San Francisco, San Francisco, California, USA.
Samson KipronoAcademic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya.
Esther E FreemanMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Infectious Diseases Institute · UGAMPATH · KEHarvard University · USIndiana University – Purdue University Indianapolis · USUniversity of Washington · USUniversity of California, San Francisco · US

Funding

NPGH LEADERs YR12: OBSSR (Greenberg, Ngwafong Mukere) & NIBIB (Lee)D43TW009345 · FIC · UNIVERSITY OF WASHINGTON · PI Dibyadyuti Datta, Chandy C. John · 2017 to 2026
$15.2M
United States-East Africa HIV-Associated Malignancy Research Center (USEAHAMRC) for Career Development and the Prevention, Early Detection and Efficient Linkage to Care for Virus-related CancersU54CA254571 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BYAKWAGA, HELEN · 2020 to 2025
$5.6M
Why do Patients Develop KSU54CA190153 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KAMBUGU, ANDREW DDUNGU, MARTIN, JEFFREY N · 2014 to 2019
$3.6M
Mentoring in patient-oriented research on HIV prevention in the US and South AfricaK24AI141036 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Ingrid Valerie Bassett · 2019 to 2026
$1.1M
Improving the Care Cascade for HIV-associated Kaposi's Sarcoma in sub-Saharan AfricaK23AI136579 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI FREEMAN, ESTHER E · 2018 to 2022
$1.1M
FIC NIH HHS D43 TW009345FIC NIH HHS D43TW009345-09S7National Institute of Allergy and Infectious Diseases K23AI136579National Institute of Allergy and Infectious Diseases K24AI141036NCI NIH HHS U54 CA190153NCI NIH HHS U54 CA25457NCI NIH HHS U54 CA254571NIAID NIH HHS K23 AI136579NIAID NIH HHS K24 AI141036
6 · The paper itself

Abstract

backgroundFor people with advanced-stage Kaposi's sarcoma (KS), a common HIV-associated malignancy in sub-Saharan Africa, mortality is estimated to be 45% within 2 years after KS diagnosis, despite increasingly wide-spread availability of antiretroviral therapy and chemotherapy. For advanced-stage KS, chemotherapy in addition to antiretroviral therapy improves outcomes and saves lives, but currently, only ~50% of people with KS in western Kenya who have an indication for chemotherapy actually receive it. This protocol describes the evaluation of a multicomponent patient navigation strategy that addresses common barriers to service penetration of and fidelity to evidence-based chemotherapy among people with advanced-stage KS in Kenya.

methodsThis is a hybrid type III effectiveness-implementation study using a non-randomized, pre- post-design nested within a longitudinal cohort. We will compare the delivery of evidence-based chemotherapy for advanced-stage KS during the period before (2016-2020) to the period after (2021-2024), the rollout of a multicomponent patient navigation strategy. The multicomponent patient navigation strategy was developed in a systematic process to address key determinants of service penetration of and fidelity to chemotherapy in western Kenya and includes (1) physical navigation and care coordination, (2) video-based education, (3) travel stipend, (4) health insurance enrollment assistance, (5) health insurance stipend, and (6) peer mentorship. We will compare the pre-navigation period to the post-navigation period to assess the impact of this multicomponent patient navigation strategy on (1) implementation outcomes: service penetration (chemotherapy initiation) and fidelity (chemotherapy completion) and (2) service and client outcomes: timeliness of cancer care, mortality, quality of life, stigma, and social support. We will also describe the implementation process and the determinants of implementation success for the multicomponent patient navigation strategy. DISCUSSION: This study addresses an urgent need for effective implementation strategies to improve the initiation and completion of evidence-based chemotherapy in advanced-stage KS. By using a clearly specified, theory-based implementation strategy and validated frameworks, this study will contribute to a more comprehensive understanding of how to improve cancer treatment in advanced-stage KS.

Indexed as

Effectiveness-implementation hybridHIV-associated malignanciesKaposi’s sarcomaLow- and middle-income countries

Identifiers

PMID35562783
PMCPMC9102240
OpenAlexW4280538962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.